Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Fineline Cube Feb 26, 2026
Company Deals

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

FDA Approves Boehringer’s Zongertinib in Record 44 Days – First Oral HER2 TKI Wins CNPV Fast‑Track

Fineline Cube Feb 27, 2026
Company Drug

Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations

Fineline Cube Feb 26, 2026
Company Medical Device

Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China

Fineline Cube Apr 8, 2024

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the...

Company Deals

Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates

Fineline Cube Apr 8, 2024

German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...

Company Deals

Johnson & Johnson Acquires Shockwave Medical in a Landmark Deal to Expand Cardiovascular Portfolio

Fineline Cube Apr 8, 2024

Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced the acquisition of Shockwave Medical...

Policy / Regulatory

China’s CDE Issues Guidelines for Semaglutide Biosimilar Clinical Trials with Weight Management Focus

Fineline Cube Apr 8, 2024

The Center for Drug Evaluation (CDE) in China has released a new set of Guidelines...

Company Drug

AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer

Fineline Cube Apr 8, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its...

Company Drug

Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients

Fineline Cube Apr 8, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...

Policy / Regulatory R&D

Beijing Unveils Comprehensive Measures to Boost Innovative Medicine Development

Fineline Cube Apr 8, 2024

The Beijing Municipal Medical Insurance Bureau, in conjunction with eight other bureaus, has announced a...

Policy / Regulatory

Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth

Fineline Cube Apr 8, 2024

In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors

Fineline Cube Apr 8, 2024

Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...

Company Drug

Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment

Fineline Cube Apr 8, 2024

The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...

Company

Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort

Fineline Cube Apr 8, 2024

Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Earns FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Apr 8, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a leading Chinese pharmaceutical company, has announced that its...

Company Deals

Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China

Fineline Cube Apr 8, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI)...

Company Drug

Sichuan Kelun-Biotech Presents Positive Results for Sacituzumab Tirumotecan at AACR 2024

Fineline Cube Apr 8, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the presentation of favorable results from...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base

Fineline Cube Apr 8, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space,...

Company Deals

Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation

Fineline Cube Apr 8, 2024

Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass...

Company Drug

Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere

Fineline Cube Apr 8, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Drug

Hinova Pharmaceuticals Receives NMPA Greenlight for HP501 Clinical Trial in Gout Patients

Fineline Cube Apr 8, 2024

Shanghai-based Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that it has received approval from the...

Company Drug

Junshi Biosciences’ Toripalimab Approved for First-Line RCC Treatment in China

Fineline Cube Apr 8, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has received a new indication approval...

Company Drug

Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis

Fineline Cube Apr 7, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II...

Posts pagination

1 … 339 340 341 … 627

Recent updates

  • FDA Approves Boehringer’s Zongertinib in Record 44 Days – First Oral HER2 TKI Wins CNPV Fast‑Track
  • WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development
  • MSD’s Prevymis Wins NMPA Approval for 200‑Day Pediatric CMV Prophylaxis – Extended Post‑Transplant Protection
  • SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement
  • NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

FDA Approves Boehringer’s Zongertinib in Record 44 Days – First Oral HER2 TKI Wins CNPV Fast‑Track

Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Others

MSD’s Prevymis Wins NMPA Approval for 200‑Day Pediatric CMV Prophylaxis – Extended Post‑Transplant Protection

Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.